Skip to content
Med Rx.

Roflumilast (Cream) interactions

Checked as Roflumilast (topical) in this data source.

Full monograph for Roflumilast (Cream)Check it against another medicine

Medicines

80 documented

Severity

Medicines documented to interact with Roflumilast (Cream), worst severity first.
MedicineSeverityMechanismEffectSources
AbametapirModerateMetabolismBased on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450…1 sources — open the full entry
Amiodarone HydrochlorideModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Amlodipine BesilateModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Amlodipine Besilate + AtenololModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Amlodipine Besilate + AtorvastatinModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Amlodipine Besilate + Benazepril HydrochlorideModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Amlodipine Besilate + Olmesartan MedoxomilModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Amlodipine Besilate + TelmisartanModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Amlodipine Besilate + ValsartanModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
AprepitantModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
AsciminibModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + LidocaineModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
BicalutamideModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Bisoprolol Fumarate + Amlodipine BesilateModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Capmatinib HydrochlorideModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
CeritinibModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Chloramphenicol (Oral)ModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Chloramphenicol + Lidocaine HydrochlorideModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
CiprofloxacinbaseOphthalmicModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Ciprofloxacin + DexamethasoneModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Ciprofloxacin + Hydrocortisone AcetateModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
ClarithromycinModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
CrizotinibModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Cyclosporine (Oral)ModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Cyproterone Acetate + Ethinyl EstradiolModerateMetabolismCoadministration with oral contraceptives containing ethinyl estradiol and gestodene may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
DanazolModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
DasatinibModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
DeferasiroxModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Dexamethasone + ChloramphenicolModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Diltiazem HydrochlorideModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Drospirenone + Ethinyl Estradiol0.02 mg0.03 mgModerateMetabolismCoadministration with oral contraceptives containing ethinyl estradiol and gestodene may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Drospirenone + Ethinyl Estradiol + LevomefolateModerateMetabolismCoadministration with oral contraceptives containing ethinyl estradiol and gestodene may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
ErythromycinLotionOralModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Esomeprazole + Amoxicillin + ClarithromycinModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Ethinyl Estradiol + Desogestrel0.02 mg0.03 mgModerateMetabolismCoadministration with oral contraceptives containing ethinyl estradiol and gestodene may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Ethinyl Estradiol + GestodeneModerateMetabolismCoadministration with oral contraceptives containing ethinyl estradiol and gestodene may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Ethinyl Estradiol + Levonorgestrel + Ferrous FumarateModerateMetabolismCoadministration with oral contraceptives containing ethinyl estradiol and gestodene may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Ethinyl Estradiol + Lynestrenol0.0375 mg0.05 mgModerateMetabolismCoadministration with oral contraceptives containing ethinyl estradiol and gestodene may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
FluconazolebaseOphthalmicModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Fluvoxamine MaleateModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Imatinib MesylateModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Indapamide + AmlodipineModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Interferon Alfa-2a [Recombinant]ModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
ItraconazoleModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
KetoconazoleModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Ketoconazole + Zinc Pyrithione + AleoveraModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Lansoprazole + Amoxicillin + ClarithromycinModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
LapatinibModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
LarotrectinibModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry
Levamlodipine MaleateModerateMetabolismCoadministration with CYP450 3A4 inhibitors or dual CYP450 3A4/1A2 inhibitors may increase the systemic exposure (AUC) to roflumilast following topical…2 sources — open the full entry

This source documents no food, condition or duplication entries for Roflumilast (Cream).